Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $117 from $113 and keeps a Buy rating on the shares. The company delivered an “impressive” revenue and margin outperformance, while its guidance is absorbing the second-half tariff impact, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $120 from $116 at RBC Capital
- Boston Scientific price target lowered to $121 from $122 at Raymond James
- Boston Scientific price target raised to $120 from $115 at Baird
- Boston Scientific’s Strong Q1 2025 Performance and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Strong Q1 2025 Performance and Growth Potential Justifies Buy Rating